液基细胞学联合HPV DNA及E6/E7 mRNA定量检测筛查宫颈病变的临床价值被引量：1

下载PDF

导出

摘要目的探讨液基细胞学（TCT）联合HPV DNA及E6/E7 mRNA定量检测在宫颈病变筛查中的价值.方法同时对303例宫颈病变筛查的样本行TCT和HPV DNA及E6/E7 mRNA定量检测,分析这三种方法在宫颈病变筛查中异同之处.结果 TCT检测细胞学阳性检出率最低,HPV DNA阳性检出率比E6/E7mRN阳性检出率稍高.受试者工作特征曲线（ROC）确定的最佳诊断临界点为43.6 copies/ml.HPV E6/E7mRNA对CIN2＋诊断的灵敏度为87.5％ [95％可信区间（CI）：47.3～99.7],特异度为87.1％（95％ CI,82.8～90.7）.结论 TCT和HPV DNA及E6/E7mRNA联合检测能够提高对宫颈病变筛查的敏感性和特异性,对防治宫颈病变有较好的临床价值.

作者陈红舟查瑶周吉航邬贤凤何剑营刘晓光

机构地区浙江省舟山医院

出处《浙江临床医学》 2015年第10期1799-1800,共2页 Zhejiang Clinical Medical Journal

关键词宫颈病变液基细胞学人乳头瘤病毒 E6/E7

分类号 R512.91 [医药卫生—内科学]

引文网络
相关文献

参考文献6

1Sn-ders PJ,Heideman DA,Meijer CJ.Methods for HPV de-tection in exfoliated cell and tissue specimens.APM1S,2010,118(6-7):521-528.
2Smith J S, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high - grade cervical lesions: A meta - analysis update. International journal of cancer, 2007, 121 (3): 621-632.
3任美英,王翠峰,付玉华.HPVE6／E7mRNA定量检测技术及其在宫颈病变中的临床应用[J].世界最新医学信息文摘,2012,12(9):50-50. 被引量：5
4赵倩颖,郄明蓉.高危型人乳头瘤病毒E6、E7mRNA检测筛检宫颈癌的价值[J].中国实用妇科与产科杂志,2013,29(10):837-840. 被引量：4
5Molden T, Kraus I, Skomedal H, et al. PreTectTM HPV-Proofer: real- time detection and typing ofE6/E7 mRNA from carcinogenic human papillomavinsses. Journal of virological methods, 2007, 142( 1 ): 204-212.
6Sotlar K, Selinka HC, Menton M, et al. Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical oncology, 1998, 69(2): scrapes by nested RT-PCR. Gynecologic 114-121.

二级参考文献26

1GRINSTEINE, WERNETP, SNIJDERSPJF, et al Nu cleo linas A etivator of Human Papillomavirus Type 18OncogeneTran-seription in Cervical Cancer[ J]. JExpMed, 2002,196 ( 8 ):1067-1078.
2Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the Ctiology of human canaer [ J]. Vaccinc , 2006,24 ( Sup-pl 3 ) : S3/1-10.
3Molden T, Nygard JF, Kraus I, et al, Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear[J]. Int J Cancer .2005,114 ( 6 ): 973-976.
4Sterdak IM, Juvet LK, Norderhaug IN, HPV RNA test for cervical cancer [R]. Rapport fra Kunnskapssenteret, NOKC nr 02-2008.
5Li J, Li LK, Ma JF, et al. Knowledge and attitudes about human papillomavirus (HPV) and HPV vaccines among women living in metropolitan and rural regions of China [ J ]. Vaccine, 2009, 27(8) :1210-1215.
6Woodman CB, Collins SI, Young IS. The natural history of cervical HPV infection: unresolved issues [ J ]. Nat Rev Cancer, 2007, 7(1) :11-22.
7Munoz N, Bosch FX, De Sanjos S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer [J]. N Engl J Med, 2003, 348(6) :518-527.
8Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus induced carcinogenesis: roles of E6 and E7 proteins [ J ]. Cancer Sci, 2007, 98 (10) : 1505-1511.
9Boulet GA, Horvath CA, Berghmans S, et al. Human papillomavirus in cervical cancer screening:important role as biomarker [J]. Cancer Epidemiol Biomarkers Prev, 2008,17 (4) :810- 817.
10Franco EL, Ferenczy A. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination [J]. Future Oncol, 2007, 3(3) :319-327.